Rothschild Investment LLC’s Accelerate Diagnostics AXDX Stock Holding History

Rothschild Investment LLC’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-160	Closed	-$112	–	3034
2025 Q1	$112	Hold	160	–	–	﹤0.01%	2953
2024 Q4	$192	Hold	160	–	–	﹤0.01%	2802
2024 Q3	$274	Hold	160	–	–	﹤0.01%	2636
2024 Q2	$187	Hold	160	–	–	﹤0.01%	2513
2024 Q1	$158	Hold	160	–	–	﹤0.01%	1869
2023 Q4	$627	Buy	+160	New	+$846	﹤0.01%	1217

Other funds holding AXDX

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

Rothschild Investment LLC's AXDX Position: Q2 2025 in Review

Rothschild Investment LLC sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 160 shares — an estimated $112 sold.

Rothschild Investment LLC first reported a position in AXDX in Q4 2023 and held it in 6 quarters. The position peaked at $627 in Q4 2023. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

Rothschild Investment LLC reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
Rothschild Investment LLC sold 160 Accelerate Diagnostics shares in Q2 2025, an estimated $112.
Rothschild Investment LLC first reported a position in Accelerate Diagnostics in Q4 2023 and held it in 6 quarters.
Rothschild Investment LLC's Accelerate Diagnostics position peaked at $627 in Q4 2023.
3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on Rothschild Investment LLC's 13F filing for Q2 2025, filed 11 Aug 2025.